Related Experiment Video

Updated: May 19, 2026

Ambulatory ECG Recording in Mice
08:00

Ambulatory ECG Recording in Mice

Published on: May 27, 2010

Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia

Nian Liu1, Carlo Napolitano, Luigi A Venetucci

  • 1Cardiovascular Genetic Program, The Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, NY 10016, USA.

Trends in Cardiovascular Medicine
|August 8, 2012
PubMed

Insights

Flecainide shows promise in preventing dangerous arrhythmias for patients with catecholaminergic polymorphic ventricular tachycardia. Its antiarrhythmic effects are thought to stem from Na(+) channel blockade and ryanodine receptor inhibition.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a life-threatening inherited arrhythmia.
  • Current therapeutic options for CPVT have limitations.
  • Flecainide has emerged as a potential treatment for CPVT.

Purpose of the Study:

  • To review the current literature on flecainide's efficacy in preventing arrhythmias in CPVT patients.
  • To summarize the proposed mechanisms of action for flecainide in CPVT.
  • To outline the ongoing debate regarding flecainide's antiarrhythmic effects.

Main Methods:

  • Literature review of studies investigating flecainide for CPVT.
  • Analysis of proposed molecular and cellular mechanisms.
  • Synthesis of evidence supporting different hypotheses.

Main Results:

  • Flecainide demonstrates potential efficacy in preventing ventricular arrhythmias in CPVT.
  • Proposed mechanisms include sodium channel (Na+) blockade.
  • Direct inhibition of the ryanodine receptor (RyR2) is another hypothesized mechanism.

Conclusions:

  • Flecainide represents a promising therapeutic strategy for CPVT.
  • Further research is needed to fully elucidate its antiarrhythmic mechanisms.
  • Understanding these mechanisms will optimize flecainide's clinical application in CPVT.

More Related Videos

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...